Past virtual events – watch on demand

Didn’t get a chance to join one of our webinars? Don’t worry, we’ve recorded each session so you can catch up on the latest breakthroughs, ongoing developments and updates in the cancer research landscape. To access the recordings please register (for free) to watch the videos on-demand. 


In conversation with…Elli Papaemmanuil

Chair: Professor Mark Lawler, Queen’s University Belfast, UK
Speaker: Dr Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center, USA

Join Dr Papaemmanuil and Mark Lawler as they discuss how big data is influencing our understanding of genomics and how it can be applied to cancer research. 


Register to watch on demand


What’s new in sarcoma research?

Chair: Dr Paul Huang, Institute of Cancer Research (ICR), UK
Speakers: Professor Bernadette Brennan, Dr Robin Jones and Professor Paolo Dei Tos

This virtual session focuses on new research in sarcoma, with particular emphasis on the results of practice-changing trials. Speakers offer updates on new data recently presented at ASCO, the new WHO sarcoma classification and its impact and influence on UK practice.


Register to watch on demand


What’s new in prostate cancer?

Chair: Professor Hashim Ahmed, Imperial College London, UK
Speakers: Professor Robert Bristow, Dr Suneil Jain and Professor Ian Mills

This session focuses on the recent advances in prostate cancer, with particular emphasis on the results of practice-changing trials. Speakers provide updates on new data recently presented at ASCO and AACR, and its impact on UK practice.


Register to watch on demand


In conversation with…Vinay Prasad

Chair: Dr Richard Simcock, Brighton and Sussex University Hospitals NHS Trust
Speaker: Dr Vinay Prasad, University of California San Francisco, USA

Join Dr Vinay Prasad and Dr Richard Simcock as they discuss ‘the good, the bad and the ugly’ in clinical research; what we can learn and what we can improve. They also explore the similarities and differences between the UK and USA systems and consider the lessons learnt so far during the COVID-19 pandemic.


Register to watch on demand


NCRI-BSI In conversation with…Karin de Visser

Chair: Dr Eileen Parkes, University of Oxford, UK
Speaker: Professor Karin de Visser, The Netherlands Cancer Institute and Leiden University, Netherlands

Join Karin as she discusses inflammation and cancer – the impact of the immune system on metastatic breast cancer and therapy response.

Jointly organised with the British Society for Immunology



Register to watch on demand


In conversation with…Eric Topol

Chair: Professor Tim Maughan, Chair of the NCRI Strategy Advisory Group, UK
Speaker: Dr Eric Topol, Scripps Research Translational Institute, USA

This session explores lessons learnt during the COVID-19 pandemic and how cancer research could improve as a result. The discussion focuses on workforce and organisation as well as how the use of data and AI could be applied to improve patient outcomes. Known challenges and opportunities are discussed with a view of offering potential solutions.

Register to watch on demand


In conversation with…William Foulkes

Chair: Dr Jaine Blayney, Queen’s University Belfast, UK
Speaker: Dr William Foulkes – McGill University, Montreal, Canada

Join William Foulkes as he discusses inherited predisposition to cancer. The discussion covers our current understanding of the genetics of various cancers and considers the risk of inherited mutations, reflecting on the role of policy in the context of prevention, screening and early detection. Consideration is given to the potential of data and AI, using exemplars such as genome-wide characterisation of patients with multiples primary tumours to identify their genetic predisposing factors.

Register to watch on demand


Radiotherapy research in the UK: What’s new? Updates on new data, impact and influence on practice

Chair: Professor Mererid Evans, Velindre University NHS Trust, UK
Speakers: Professor Chris Nutting, Professor Paula Ghaneh and Dr Duncan Wheatley

This virtual session updates the community on recent discoveries from radiotherapy trials. Presenters bring the research into context and explain what it means in practice, considering the challenges and opportunities of implementing it on a large scale and the potential benefits to patients. Trials in head and neck, breast and pancreas are discussed.

Register to watch on demand

Cancer care at the time of COVID-19

Chair: Emma Kinloch, Chair of NCRI Consumer Forum, UK
Professor Mark Lawler, Professor Peter Johnson, Margaret Grayson and Professor Tom Crosby

This session aims to discuss the challenges that cancer care has been experiencing and opportunities that may arise as a result of the COVID-19 crisis. Panellists will discuss recent data finding and contextualise it to offer potential solutions and consider priorities and new approaches going forward.

Register to watch on demand

In conversation with…Patricia Ganz

Chair: Dr Alexandra Gilbert, University of Leeds, UK
Speaker: Dr Patricia Ganz, University of California Los Angeles, USA

Join Patricia Ganz as she considers the assessment of the quality of life in cancer patients, using breast cancer as an exemplar. The discussion covers important topics such as cancer survivorship and late effects of cancer treatment, cancer in the elderly and quality of care for cancer patients. Consideration is given to the similarities and differences between the US and UK systems and focuses on how patients’ needs are given centre stage.

AstraZeneca has provided a sponsorship grant towards this independent Programme




Register to watch on demand

The promise of particle therapy: What’s new and where are we going?

Chair: Professor Chris Nutting, The Royal Marsden NHS Foundation Trust, UK
Speakers: Professor Neil Burnet, Dr Helen Bulbeck, Professor Markus Stock, Bethany Rothwell, Dr Matthew Lowe

This session looks at several areas of interest in particle therapy research; the speakers discuss the development of proton beam clinical trials including trial design and patient and public involvement, as well as horizon scanning for opportunities involving carbon ion and Flash.

Register to watch on demand


In conversation with…Stephen Baylin

Chair: Dr Adone Mohd Sarip, Queen’s University Belfast, UK
Speaker: Dr Stephen Baylin, Johns Hopkins University, USA

Join Stephen as he explores the role of epigenetics in cell behaviour, and specifically how cellular biology and the genetics of cancer can be exploited to silence tumour suppressor genes and reduce tumour progression. The discussion will cover how these discoveries could be utilised in the context of cancer prevention as well as therapeutics and consider the key unanswered questions to make further progress.

Register to watch on demand


Screening and early detection of cancer: How do we do it better?

Chair: Emma Kinloch, Chair of NCRI Consumer Forum, UK
Speakers: Professor Stan Kaye, Professor Peter Sasieni, Dr Jo Waller, Professor Richard Neal

This session aims to discuss the future of screening programmes and early detection of cancer and consider innovative ways to improve reach, patient uptake and research efforts in order to mitigate the devastating effects of cancer in the population. Particular attention will be given to the context of the COVID-19 pandemic, what we learnt and how things might need to change to improve outcomes going forward.


Optimising care for people living with and beyond cancer

Date: Thursday 24 September 2020
Time: 13:00 -14:00 (BST)
Chair: Professor Claire Foster, University of Southampton, UK
Speakers: Professor Galina Velikova, Roger Wilson, Professor Afaf Girgis, Dr Nicola Gray

This session will focus on the importance and value of Patient Reported Outcomes (PROs) in cutting edge cancer research and enhanced personalised care. Speakers will discuss the potential barriers to the collection and use of PROs and how these might be addressed, and give examples of instances where PROs have been used to inform and improve the care of people living with cancer. They’ll also discuss the lessons learnt in doing this successfully; implications of COVID-19 pandemic and opportunities for the future.